Yan Zheng1, Yanping Li1, Eric B Rimm2, Frank B Hu2, Christine M Albert3, Kathryn M Rexrode3, JoAnn E Manson4, Lu Qi5. 1. Departments of Nutrition and. 2. Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Channing Division of Network Medicine and. 3. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and. 4. Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Channing Division of Network Medicine and Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and. 5. Departments of Nutrition and Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA lqi1@tulane.edu.
Abstract
BACKGROUND: The trimethylamine-containing nutrient phosphatidylcholine is the major dietary source for the gut microbiota metabolite trimethylamine-N-oxide (TMAO), which has been related to cardiovascular diseases (CVDs) and mortality. Previous research suggested that the relation of TMAO with CVD risk might be stronger in diabetic than in nondiabetic populations. However, the evidence for an association of dietary phosphatidylcholine with CVD and mortality is limited. OBJECTIVES: We aimed to examine whether dietary consumption of phosphatidylcholine, which is mainly derived from eggs, red meat, and fish, is related to all-cause and CVD mortality in 2 cohorts of US women and men. In particular, we also tested if such an association was modified by diabetes status. DESIGN: We followed 80,978 women from the Nurses' Health Study (1980-2012) and 39,434 men from the Health Professionals Follow-Up Study (1986-2012), who were free of cancer and CVD at baseline, for mortality. Dietary intakes and potential confounders were assessed with regularly administered questionnaires. We used Cox proportional hazards models to estimate HRs and 95% CIs. RESULTS: We documented 17,829 all-cause and 4359 CVD deaths during follow-up. After multivariate adjustment for potential confounders, including demographic factors, disease status, lifestyle, and dietary intakes, higher phosphatidylcholine intakes were associated with an increased risk of all-cause and CVD mortality. HRs (95% CIs) comparing the top and bottom quintiles of phosphatidylcholine intake were 1.11 (1.06, 1.17; P-trend across quintiles < 0.0001) for all-cause mortality and 1.26 (1.15, 1.39; P-trend < 0.0001) for CVD mortality in the combined data of both cohorts. The associations of phosphatidylcholine with all-cause and CVD mortality were stronger in diabetic than in nondiabetic participants (P-interaction = 0.0002 and 0.001, respectively). CONCLUSION: These data suggest that higher phosphatidylcholine consumption is associated with increased all-cause and CVD mortality in the US population, especially in patients with diabetes, independent of traditional risk factors.
BACKGROUND: The trimethylamine-containing nutrient phosphatidylcholine is the major dietary source for the gut microbiota metabolite trimethylamine-N-oxide (TMAO), which has been related to cardiovascular diseases (CVDs) and mortality. Previous research suggested that the relation of TMAO with CVD risk might be stronger in diabetic than in nondiabetic populations. However, the evidence for an association of dietary phosphatidylcholine with CVD and mortality is limited. OBJECTIVES: We aimed to examine whether dietary consumption of phosphatidylcholine, which is mainly derived from eggs, red meat, and fish, is related to all-cause and CVD mortality in 2 cohorts of US women and men. In particular, we also tested if such an association was modified by diabetes status. DESIGN: We followed 80,978 women from the Nurses' Health Study (1980-2012) and 39,434 men from the Health Professionals Follow-Up Study (1986-2012), who were free of cancer and CVD at baseline, for mortality. Dietary intakes and potential confounders were assessed with regularly administered questionnaires. We used Cox proportional hazards models to estimate HRs and 95% CIs. RESULTS: We documented 17,829 all-cause and 4359 CVD deaths during follow-up. After multivariate adjustment for potential confounders, including demographic factors, disease status, lifestyle, and dietary intakes, higher phosphatidylcholine intakes were associated with an increased risk of all-cause and CVD mortality. HRs (95% CIs) comparing the top and bottom quintiles of phosphatidylcholine intake were 1.11 (1.06, 1.17; P-trend across quintiles < 0.0001) for all-cause mortality and 1.26 (1.15, 1.39; P-trend < 0.0001) for CVD mortality in the combined data of both cohorts. The associations of phosphatidylcholine with all-cause and CVD mortality were stronger in diabetic than in nondiabetic participants (P-interaction = 0.0002 and 0.001, respectively). CONCLUSION: These data suggest that higher phosphatidylcholine consumption is associated with increased all-cause and CVD mortality in the US population, especially in patients with diabetes, independent of traditional risk factors.
Authors: E B Rimm; E L Giovannucci; W C Willett; G A Colditz; A Ascherio; B Rosner; M J Stampfer Journal: Lancet Date: 1991-08-24 Impact factor: 79.321
Authors: W H Wilson Tang; Zeneng Wang; Bruce S Levison; Robert A Koeth; Earl B Britt; Xiaoming Fu; Yuping Wu; Stanley L Hazen Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245
Authors: Yanping Li; Dong D Wang; Stephanie E Chiuve; JoAnn E Manson; Walter C Willett; Frank B Hu; Lu Qi Journal: Diabetes Care Date: 2015-02 Impact factor: 19.112
Authors: Daniel T Dibaba; Karen C Johnson; Anna M Kucharska-Newton; Katie Meyer; Steven H Zeisel; Aurelian Bidulescu Journal: Diabetes Care Date: 2020-09-08 Impact factor: 19.112
Authors: Xinmin S Li; Slayman Obeid; Roland Klingenberg; Baris Gencer; François Mach; Lorenz Räber; Stephan Windecker; Nicolas Rodondi; David Nanchen; Olivier Muller; Melroy X Miranda; Christian M Matter; Yuping Wu; Lin Li; Zeneng Wang; Hassan S Alamri; Valentin Gogonea; Yoon-Mi Chung; W H Wilson Tang; Stanley L Hazen; Thomas F Lüscher Journal: Eur Heart J Date: 2017-03-14 Impact factor: 29.983
Authors: Gretchen N Wiese; Annabel Biruete; Ranjani N Moorthi; Sharon M Moe; Stephen R Lindemann; Kathleen M Hill Gallant Journal: J Ren Nutr Date: 2020-06-29 Impact factor: 3.655
Authors: Jennifer Wilcox; Sarah M Skye; Brett Graham; Allyson Zabell; Xinmin S Li; Lin Li; Shamanthika Shelkay; Xiaoming Fu; Sarah Neale; Cathy O'Laughlin; Kimberly Peterson; Stanley L Hazen; W H Wilson Tang Journal: Am J Med Date: 2021-04-17 Impact factor: 5.928